Intranasal Chlorpheniramine Maleate for the treatment of COVID-19: Translational and Clinical Evidence
Main Article Content
Abstract
Recently, the nasal cavity has been highlighted as an ideal route of administration for interventions as it is the portal of entry of the severe acute respiratory syndrome coronavirus (SARS-CoV-2). The present study aimed to demonstrate the feasibility and efficacy of intranasally administered Chlorpheniramine Maleate (CPM) spray to treat coronavirus disease 2019 (COVID-19).
Methods: The present study used a two-phase, non-clinical to clinical approach. The non-clinical phase evaluated CPM’s antiviral activity against SARS-CoV-2 delta (B.1.617.2) strain via a highly differentiated three-dimensional in vitro model of normal, human-derived tracheal/bronchial epithelial cells. CPM was tested in duplicate inserts of the tissue models of the human airway. Virus yield reduction assays measured antiviral activity on day six after infection. For the clinical phase, COVID-19 symptomatic (polymerase chain reaction positive) patients were recruited and assigned to a 7-day CPM treatment (n=32) or placebo (PLB; n=13). Close safety monitoring of all patients was conducted before and after administering the drug. The primary outcomes monitored were time to symptom resolution (days), progression to hospitalization, emergency room visits, and symptoms of the severity of the disease using a visual analog scale (VAS) on a scale of 1-10 (no symptoms to worst symptoms).
Results: The virus yielded a reduction in the assay such that the CPM solution log reduction value was 2.69 and Remdesivir 0.12, demonstrating much high antiviral activity of CPM. Results of the clinical phase demonstrate that VAS scores between the groups were evident after using CPM for two days (day 3). The CPM group VAS were significantly lower (P<0.001) starting from day three compared with day one. In contrast, there were no statistically significant (P>0.05) changes in the PLB during the 7-day treatment window. No subjects in the intervention group were hospitalized, while two in the PLB required hospitalization (15.4%; X2=5.15, P=0.023). Besides some mild discomfort felt by subjects immediately after applying the spray, the participants reported neither adverse reactions nor side effects.
Conclusion: If taken together, the results of the present two-phase study point towards the conclusion that CPM is an antiviral agent that can be administered intranasally to treat COVID-19 effectively.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Wilson JG, Simpson LJ, Ferreira AM, et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight. Sep 3 2020;5(17)doi:10.1172/jci.insight.140289
3. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. Mar 12 2020;doi:10.1093/cid/ciaa248
4. Wu M-L, Liu F-L, Sun J, et al. SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury. Signal Transduction and Targeted Therapy. 2021/12/17 2021;6(1):428. doi:10.1038/s41392-021-00849-0
5. Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. Dec 2005;79(23):14614-21. doi:10.1128/jvi.79.23.14614-14621.2005
6. Pilicheva B, Boyuklieva R. Can the Nasal Cavity Help Tackle COVID-19? Pharmaceutics. Oct 3 2021;13(10)doi:10.3390/pharmaceutics13101612
7. Ferrer G, Sanchez-Gonzalez MA. Effective Nasal Disinfection as an Overlooked Strategy in Our Fight against COVID-19. Ear Nose Throat J. Mar 26 2021:1455613211002929. doi:10.1177/01455613211002929
8. Hou YJ, Okuda K, Edwards CE, et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. Jul 23 2020;182(2):429-446.e14. doi:10.1016/j.cell.2020.05.042
9. Torres J, Go C, Camacho G, Sanchez-Gonzalez M, Ferrer G. Chlorpheniramine Maleate Nasal Spray In COVID-19 Patients: Case Series. J Clin Exp Pharmacol. 2021;10(2)(275):3. doi:10.35248/2161-1459.21.10.275
10. Westover JB, Ferrer G, Vazquez H, Bethencourt-Mirabal A, Go CC. In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2. Cureus. Sep 17 2020;12(9):e10501. doi:10.7759/cureus.10501
11. Mostafa A, Kandeil A, Y AMME, et al. FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. Pharmaceuticals (Basel). Dec 4 2020;13(12)doi:10.3390/ph13120443
12. Xu W, Xia S, Pu J, et al. The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. Front Microbiol. 2018;9:2643. doi:10.3389/fmicb.2018.02643
13. Ekins S, Freundlich JS, Coffee M. A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus. F1000Res. 2014;3:277. doi:10.12688/f1000research.5741.2
14. Black S. Molecular Modeling and Preliminary Clinical Data Suggesting Antiviral Activity for Chlorpheniramine (Chlorphenamine) Against COVID-19. Cureus. 2022;14(1):e20980. doi:10.7759/cureus.20980
15. Morán Blanco JI, Alvarenga Bonilla JA, Homma S, Suzuki K, Fremont-Smith P, Villar Gómez de Las Heras K. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients. Pulm Pharmacol Ther. Jan 16 2021;67:101989. doi:10.1016/j.pupt.2021.101989
16. Sanchez-Gonzalez M, Rizvi SA, Torres J, Ferrer G. A Randomized Controlled Pilot Trial to Test the Efficacy of Intranasal Chlorpheniramine Maleate With Xylitol for the Treatment of Allergic Rhinitis. Cureus. Mar 31 2021;13(3):e14206. doi:10.7759/cureus.14206
17. Reed LJ, Muench H. A Simple method of estimating fifty per cent endpoints12. American Journal of Epidemiology. 1938;27(3):493-497. doi:10.1093/oxfordjournals.aje.a118408
18. Basu S. Computational characterization of inhaled droplet transport to the nasopharynx. Sci Rep. Mar 23 2021;11(1):6652. doi:10.1038/s41598-021-85765-7
19. Basu S, Holbrook LT, Kudlaty K, et al. Numerical evaluation of spray position for improved nasal drug delivery. Scientific Reports. 2020/06/29 2020;10(1):10568. doi:10.1038/s41598-020-66716-0
20. Yang L, Pei R-j, Li H, et al. Identification of SARS-CoV-2 entry inhibitors among already approved drugs. Acta Pharmacologica Sinica. 2020/10/28 2020;doi:10.1038/s41401-020-00556-6
21. Reznikov LR, Norris MH, Vashisht R, et al. Identification of antiviral antihistamines for COVID-19 repurposing. Biochem Biophys Res Commun. Jan 29 2021;538:173-179. doi:10.1016/j.bbrc.2020.11.095
22. Zarkoob H, Allué-Guardia A, Chen YC, et al. Modeling SARS-CoV-2 and Influenza Infections and Antiviral Treatments in Human Lung Epithelial Tissue Equivalents. bioRxiv. May 12 2021;doi:10.1101/2021.05.11.443693
23. Kirkegaard J, Secher C, Borum P, Mygind N. Inhibition of histamine-induced nasal symptoms by the H1 antihistamine chlorpheniramine maleate: demonstration of topical effect. Br J Dis Chest. Apr 1983;77(2):113-22. doi:10.1016/0007-0971(83)90017-7
24. Galal I, Hussein AARM, Amin MT, et al. Determinants of persistent post-COVID-19 symptoms: value of a novel COVID-19 symptom score. The Egyptian Journal of Bronchology. 2021;15(1):10. doi:10.1186/s43168-020-00049-4
25. Mangal V, Murari T, Vashisht R, et al. Olfactory Dysfunction Among Asymptomatic Patients with SARS CoV2 Infection: A Case-Control Study. Indian J Otolaryngol Head Neck Surg. Feb 10 2021:1-6. doi:10.1007/s12070-021-02366-6
26. Graham AC, Temple RM, Obar JJ. Mast Cells and Influenza A Virus: Association with Allergic Responses and Beyond. Review. Frontiers in Immunology. 2015-May-18 2015;6doi:10.3389/fimmu.2015.00238
27. Van Toor BS, Buchwald A, Stengele E, Trenk D, Gercek C, de Mey CM. Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally. International journal of clinical pharmacology and therapeutics. Apr 2001;39(4):173-8. doi:10.5414/cpp39173
28. Eldanasory OA, Eljaaly K, Memish ZA, Al-Tawfiq JA. Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19. Travel Med Infect Dis. Sep-Oct 2020;37:101874. doi:10.1016/j.tmaid.2020.101874
29. Branco ACCC, Yoshikawa FSY, Pietrobon AJ, Sato MN. Role of Histamine in Modulating the Immune Response and Inflammation. Mediators of Inflammation. 2018/08/27 2018;2018:9524075. doi:10.1155/2018/9524075
30. Doyle WJ, Skoner DP, Gentile D. Nasal cytokines as mediators of illness during the common cold. Current Allergy and Asthma Reports. 2005/05/01 2005;5(3):173-181. doi:10.1007/s11882-005-0034-8
31. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. Aug 2020;26(8):1200-1204. doi:10.1038/s41591-020-0965-6
32. Taha MA, Hall CA, Shortess CJ, Rathbone RF, Barham HP. Treatment Protocol for COVID-19 Based on T2R Phenotype. Viruses. Mar 18 2021;13(3)doi:10.3390/v13030503
33. Li X, Zhang C, Liu L, Gu M. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. Faseb j. May 2020;34(5):6008-6016. doi:10.1096/fj.202000502
34. Kumar SA, Cheng W. A hypothesis: Bitter taste receptors as a therapeutic target for the clinical symptoms of SARS-CoV-2. Pharmazie. Feb 25 2021;76(2):43-54. doi:10.1691/ph.2021.0840